<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210103</url>
  </required_header>
  <id_info>
    <org_study_id>ORATOR2</org_study_id>
    <nct_id>NCT03210103</nct_id>
  </id_info>
  <brief_title>Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer</brief_title>
  <acronym>ORATOR2</acronym>
  <official_title>A Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery (ORATOR II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this randomized treatment de-escalation study is to formally compare outcomes in&#xD;
      HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary&#xD;
      surgical approach, to provide a high level of evidence to guide the selection of treatment&#xD;
      options for a subsequent phase III trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this randomized treatment de-escalation study is to formally compare outcomes in&#xD;
      HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary&#xD;
      surgical approach, to provide a high level of evidence to guide the selection of treatment&#xD;
      options for a subsequent phase III trial&#xD;
&#xD;
      The study will compare overall survival rates relative to historical controls for&#xD;
      de-intensified primary radiotherapy [60 GY +/- chemotherapy] versus transoral surgery (TOS)&#xD;
      and neck dissection [+/- adjuvant 50Gy radiotherapy] in patients with early T-stage&#xD;
      HPV-positive squamous cell carcinoma of the oropharynx and to compare quality of life (QOL)&#xD;
      profiles.&#xD;
&#xD;
      The study will require a sample size of 140 patients randomized in a 1:1 ratio between the&#xD;
      two arms. Arm 1 (radiotherapy +/1 chemotherapy) and Arm 2 (TOS)&#xD;
&#xD;
      Patients will be followed for a total of 5 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 26, 2018</start_date>
  <completion_date type="Anticipated">August 15, 2028</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 Arm study randomized in a 1:1 ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomization to death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life 1 year post treatment</measure>
    <time_frame>1 year post treatment</time_frame>
    <description>Quality of life 1 year post treatment as assessed with the MD Anderson Dysphagia Inventory (MDADI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival comparison with historical controls</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline to 5 years follow up</time_frame>
    <description>Quality of Life using the following questionnaire: MD Anderson Dysphagia Inventory (MDADI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline to 5 years follow up</time_frame>
    <description>Quality of Life using the following questionnaire: EORTC QLQ C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline to 5 years follow up</time_frame>
    <description>Quality of Life using the following questionnaire: H&amp;N35 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline to 5 years follow up</time_frame>
    <description>Quality of Life using the following questionnaire: Voice Handicap Index (VHI-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline to 5 years follow up</time_frame>
    <description>Quality of Life using the following questionnaire: Neck Dissection Impairment Index (NDII)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline to 5 years follow up</time_frame>
    <description>Quality of Life using the following questionnaire: Patient Neurotoxicity Questionnaire (PNQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity profile of both study arms using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 4</measure>
    <time_frame>Randomization until 5 years follow up</time_frame>
    <description>To determine to toxicity profile of both study arms using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feeding tube rate at 1 year</measure>
    <time_frame>baseline to 1 year post treatment</time_frame>
    <description>Measure other functional measurements such as feeding tube rate at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTCAE Dysphagia grade</measure>
    <time_frame>baseline to 5 years post treatment</time_frame>
    <description>Measure other functional measurements such as CTCAE Dysphagia grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech intelligibility</measure>
    <time_frame>baseline to 5 years post treatment</time_frame>
    <description>Measure other functional measurements such as speech intelligibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalcy of diet</measure>
    <time_frame>baseline to 5 years post treatment</time_frame>
    <description>Measure other functional measurements such as normalcy of diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 year progression-free survival comparison between Arm 1 and Arm 2</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomization to disease progress at any site or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1, Radiation +/- Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Treatment (Radiation +/- Chemotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2, TOS + Neck Dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Standard of Care: Radiation +/- Chemotherapy</description>
    <arm_group_label>Arm 1, Radiation +/- Chemotherapy</arm_group_label>
    <other_name>Chemotherapy, if required</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transoral Surgery (TOS) + Neck Dissection</intervention_name>
    <description>Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)</description>
    <arm_group_label>Arm 2, TOS + Neck Dissection</arm_group_label>
    <other_name>Radiation, if required</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  willing to provide informed consent&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma&#xD;
&#xD;
          -  P16 positive, or HPV positive&#xD;
&#xD;
          -  Primary tumor site in the oropharynx (includes tonsil, soft palate, base of tongue,&#xD;
             walls of oropharynx)&#xD;
&#xD;
          -  Eligible for curative intent treatment, with likely negative resection margins at&#xD;
             surgery. For patients where adequate transoral access is in question, they will first&#xD;
             undergo an examination under anesthesia prior to randomization to ensure adequate&#xD;
             exposure can be obtained.&#xD;
&#xD;
          -  Smokers and non-smokers are included. Patients will be stratified by ,&lt;10 pack years&#xD;
             smoking history versus &gt; or equal to 10 pack years.&#xD;
&#xD;
          -  Tumor stage (AJCC 8th edition): T1 or T2&#xD;
&#xD;
          -  Nodal stage (AJCC 8th edition): N0, N1, or N2&#xD;
&#xD;
          -  For patients who may require chemotherapy (ie, patients with multiple lymph nodes&#xD;
             positive or a single node more than 3 cm in size, in any plane, CBC/differential&#xD;
             within 4 weeks prior to randomization with adequate bone marrow function, hepatic, and&#xD;
             renal function defined as: Hemoglobin ≥ 80 g/L; Absolute neutrophil count ≥ 1.5 x 10&#xD;
             9/L, platelets ≥ 100 x 10 9/L, bilirubin ≤ 35 umol/L, AST or ALT ≤ 3 x the upper limit&#xD;
             of normal; serum creatinine ≤ 130 umol/L or creatinine clearance ≥ 50 ml/min&#xD;
&#xD;
          -  patients assessed at head and neck multidisciplinary clinic (with assessment by&#xD;
             radiation oncologist and surgeon) and presented at multidisciplinary tumor board prior&#xD;
             to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unambiguous clinical or radiological evidence of extranodaal extension on&#xD;
             pre-treatment imaging. This includes the presence of matted notes, defined as 3 or&#xD;
             more nodes that are abutting with loss of intervening fat planes&#xD;
&#xD;
          -  Serious medical comorbidities or other contraindications to radiotherapy, chemotherapy&#xD;
             or surgery&#xD;
&#xD;
          -  prior history of head and neck cancer within 5 years&#xD;
&#xD;
          -  prior head and neck radiation at any time&#xD;
&#xD;
          -  metastatic disease&#xD;
&#xD;
          -  inability to attend full course of radiotherapy or follow up visits&#xD;
&#xD;
          -  prior invasive malignant disease unless disease-free for at least 5 years or more,&#xD;
             with the exception of non-melanoma skin cancer&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Palma</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>July 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transoral Surgery</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

